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Abstract
The display of foreign proteins on the surface of baculovirus virions has provided a tool for the analysis of protein–protein interactions
and for cell-specific targeting in gene transfer applications. To evaluate the baculovirus display system as a vaccine vehicle, we have
generated a recombinant baculovirus (AcNPV-CSPsurf) that displays rodent malaria Plasmodium berghei circumsporozoite protein (PbCSP)
on the virion surface as a fusion protein with the major baculovirus envelope glycoprotein gp64. The PbCSP-gp64 fusion protein was
incorporated and oligomerized on the virion surface and led to a 12-fold increase in the binding activity of AcNPV-CSPsurf virions to
HepG2 cells. Immunization with adjuvant-free AcNPV-CSPsurf virions induced high levels of antibodies and gamma interferon-secreting
cells against PbCSP and protected 60% of mice against sporozoite challenge. These data demonstrate that AcNPV-CSPsurf displays
sporozoite-like PbCSP on the virion surface and possesses dual potentials as a malaria vaccine candidate and a liver-directed gene delivery
vehicle.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Recently, the baculovirus Autographa californica nu-
clear polyhedrosis virus (AcNPV) has been shown to be
capable of displaying a foreign protein on the virion surface
(Grabherr et al., 2001). This display system is achieved by
using the major surface glycoprotein of AcNPV, gp64, to
display foreign proteins on the virion surface by in-frame
fusion between the gp64 signal sequence and mature foreign
protein domain. For example, the external domain of HIV
envelope protein gp120 was displayed on the virion surface
(Boublik et al., 1995). The displayed gp120 was oligomer-
ized on the tip of virions in an active form and possessed
binding activity for its ligand, CD4. A baculovirus display-
ing a functional single-chain antibody fragment specific for
the carcinoembryonic antigen targeted to adenocarcinoma
cells has also been reported, indicating that baculovirus
displaying specific ligand-binding proteins may serve as an
effective tool for targeted gene therapy to specific cells
(Mottershead et al., 2000).
The baculovirus display system has several potential
advantages as a vaccine vehicle. The use of purified virions
as immunogens alleviates the need for additional extraneous
adjuvants to the vaccine formulation due to the intrinsic
immunostimulatory effect often associated with viral immu-
nogens. Additionally, the presentation of an antigen in its
proper conformation on the virion surface makes it readily
accessible for interactions with cellular components of the
immune system. In fact, pathogen antigens such as the HIV
envelope protein gp41 (Boublik et al., 1995), rubella virus
envelope protein (Mottershead et al., 1997), foot-and-mouth
disease virus capsid protein (Tami et al., 2000), and Thei-
leria parva p67 antigen (Kaba et al., 2003) have been ex-
* Corresponding author. Division of Medical Zoology, Department of
Infection and Immunity, Jichi Medical School, Tochigi 329-0498, Japan.
Fax: 81-285-44-6489.
E-mail address: shigeto@jichi.ac.jp (S. Yoshida).
R
Available online at www.sciencedirect.com
Virology 316 (2003) 161–170 www.elsevier.com/locate/yviro
0042-6822/$ – see front matter © 2003 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2003.08.003
pressed using this system, and some of them induced high
titers of antigen-specific antibodies. To our knowledge,
however, the efficacy of the baculovirus display system as a
protective vaccine delivery system has not been previously
reported.
Baculoviruses have an additional potential for gene de-
livery to mammalian cells. The host specificity of baculo-
virus was originally thought to be restricted to arthropods;
however, it has been shown that AcNPV can introduce
foreign genes into mammalian cell lines, including hepato-
cytes (Boyce and Bucher, 1996; Hofmann et al., 1995) and
other cell types (Shoji et al., 1997). The major prerequisite
for generating recombinant baculoviruses for liver- and
non-liver-directed gene transfers is the insertion of a mam-
malian expression cassette into the virus genome (Condreay
et al., 1999). Under these conditions, the transduction effi-
cacy reached 100% in human hepatocytes ex vivo (Sandig
et al., 1996). The binding of baculovirus to mammalian cells
may involve the interaction of gp64 with phospholipids on
the cell surface (Tani et al., 2001). Thus, baculovirus pos-
sesses two major characteristics relevant to vaccine appli-
cations: the display of foreign proteins on the virion surface
and the ability to serve as a vehicle for gene transfer to
mammalian cells in the absence of cytotoxicity and viral
replication.
Malaria kills between 1.5 and 2.7 million people each
year, and between 300 and 500 million others fall ill from it,
often severely. Clearly, the development of an effective
vaccine would greatly facilitate worldwide control of this
important parasitic disease. We have focused on developing
a novel malaria vaccine based on the circumsporozoite
protein (CSP), the major surface antigen of the infective
sporozoite stage (Yoshida et al., 2000). Antibodies directed
against CSP inhibit the invasion of hepatocytes by sporo-
zoites and CSP-specific CD8 T cells kill sporozoite-in-
fected hepatocytes (Hoffman et al., 1996). CSP-specific
protective immune responses have been induced with vari-
ous types of subunit vaccines, including synthetic peptides,
bacterial and viral vectors, and DNA vaccines (Doolan and
Hoffman, 1997; Hoffman et al., 1996). In terms of its
biological function, CSP appears to be involved in sporo-
zoite adherence to hepatocytes. Within minutes after enter-
ing a blood capillary via a mosquito bite, the sporozoites
travel through the bloodstream to the liver where they in-
vade their target cells, the hepatocytes (Sinnis, 1996). This
liver-specific invasion is mainly attributed to the region
II-plus of CSP, which binds to heparan sulfate proteogly-
cans (HSPGs) on the hepatocyte membrane (Cerami et al.,
1994). Thus, CSP functions both as an immunogen capable
of inducing protective immunity and a ligand for liver
membrane receptors.
Our strategy for malaria vaccine development is to gen-
erate a “sporozoite-like” CSP particle using the baculovirus
display system. Immunization with these “sporozoite-like”
CSP particles is expected to elicit both neutralizing antibod-
ies and protective cellular immune responses resulting from
the effective presentation by antigen-presenting cells. To
that end, in this work, we generated a recombinant baculo-
virus displaying CSP on the virion surface. These recombi-
nant baculovirus virions specifically bound to HepG2 cells
through HSPGs. The immunization of mice with the bacu-
lovirus virions displaying PbCSP elicited specific antibodies
and gamma interferon (IFN-) production and conferred
protection against Plasmodium berghei challenge infection.
Results
Expression of CSP-gp64 fusion protein and display on the
virion surface
The P. berghei circumsporozoite protein (PbCSP) gene
fragment encoding amino acids 21–306, which lacks its
signal peptide and hydrophobic C-terminal region, was in-
serted into the pBACsurf vector to express the PbCSP-gp64
fusion protein on the virion surface. As a control virion
without PbCSP at its surface, the same fragment of the
PbCSP gene was inserted into the pBACgus1 vector. Re-
combinant baculoviruses AcNPV-CSP and AcNPV-CSP-
surf were generated by cotransfection with pBACgus-CSP
and pBACsurf-CSP, respectively. Fig. 1 shows a schematic
diagram of the rPbCSP and PbCSP-gp64 fusion proteins.
Both proteins contain a FLAG epitope tag at the N-terminus
to facilitate their detection.
Lysates of Sf9 cells infected with the recombinant bacu-
loviruses were prepared and lysate proteins were separated
by SDS–PAGE followed by immunoblot analysis using the
anti-PbCSP monoclonal antibody (MAb) (Fig. 2A) and anti-
FLAG MAb (Fig. 2B). Both anti-PbCSP MAb and anti-
FLAG MAb recognized rPbCSP expressed by AcNPV-CSP
as a doublet with relative molecular masses (Mr) of 48 and
52 kDa (Figs. 2A and B, lanes 2 and 6, respectively), which
may be due to posttranslational modification or to degrada-
tion. AcNPV-CSPsurf expressed a PbCSP-gp64 fusion pro-
tein with an Mr of 120 kDa in infected Sf9 cells (Figs. 2A
and B, lanes 3 and 7). As a positive control, the native
PbCSP of sporozoites with an Mr of 44 kDa was reacted
with anti-PbCSP MAb (Fig. 2A, lane 1).
Fig. 1. PbCSP expressed by recombinant baculoviruses shown by sche-
matic representations of rPbCSP and PbCSP-gp64 fusion proteins ex-
pressed by AcNPV-CSP and AcNPV-CSPsurf, respectively. Numbers in-
dicate the amino acid positions of each protein. Bold lines indicate
junctions. SPmellitin, signal leader peptide of mellitin from honey bees;
SP64, signal leader peptide of baculovirus gp64; FLAG, FLAG epitope tag
(DYKDDDDK); CS21-306, PbCSP corresponding to amino acids 21 to 306.
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To determine whether the PbCSP-gp64 fusion protein is
incorporated into the AcNPV virions, budded baculovirus
virions were purified from culture supernatants using a
10–60% sucrose gradient and were analyzed by Western
blotting using anti-PbCSP MAb (Fig. 2C) or anti-gp64
MAb (Fig. 2D). The 120-kDa fusion protein was detected
by anti-PbCSP MAb (Fig. 2C, lane 2). In contrast, no band
reactive with anti-PbCSP MAb was seen for purified Ac-
NPV-CSP virions (Fig. 2C, lane 1). Anti-gp64 MAb recog-
nized both the PbCSP-gp64 fusion protein and native gp64
in AcNPV-CSPsurf virions, whereas only native gp64 was
detected in AcNPV-CSP virions (Fig. 2D). These data
clearly indicate that CSP is incorporated into AcNPV-CSP-
surf virions as a CSP-gp64 fusion protein, whereas CSP
does not exist in AcNPV-CSP virions.
Direct binding of AcNPV-CSPsurf virions to HepG2 cells
Cerami et al. (1994) demonstrated that CSP on the sporo-
zoite surface serves as the hepatocyte-binding ligand by
virtue of its binding to membrane HSPG. To determine
whether AcNPV-CSPsurf virions could interact with hepa-
tocytes in a similar manner, we first examined whether
PbCSP-gp64 fusion protein incorporated into the virion was
capable of binding to HepG2 cells with a specificity similar
to sporozoite CSP. Fig. 3 shows that the binding activity of
AcNPV-CSPsurf virions to HepG2 is 12-fold higher than
those of wild-type AcNPV and AcNPV-CSP virions (non-
treatment), indicating that the CSP-gp64 fusion protein is
displayed on the surface of AcNPV-CSPsurf virions. Sec-
ond, since region II-plus at C-terminus of CSP is required
for sporozoite binding to hepatocytes, we examined whether
the binding of AcNPV-CSPsurf virions to the HepG2 cell
was similarly dependent on an interaction with CSP region
II-plus. Virion binding was reduced by 50% in the presence
of the region II-plus peptide (region II-plus peptide), indi-
cating that interaction of the virion PbCSP-gp64 fusion
protein with HepG2 cells specifically involves the CSP
region II-plus. Third, we examined whether hepatocyte sur-
face HSPGs act as receptors for the PbCSP-gp64 fusion
protein. Preincubation of AcNPV-CSPsurf virions with hep-
arin caused 80% binding inhibition. Furthermore, pretreat-
ment of HepG2 cells with heparinase I resulted in 58%
binding inhibition. Since the binding effect was examined at
the highest concentration of virus virions prepared, it is not
sufficient to show that the binding effect could be saturated.
However, the degree of binding inhibition by region II-plus,
heparin, and heparinase I is consistent with that observed for
CSP mutants of P. falciparum (Rathore and McCutchan,
2000). Recently, Rathore et al. (2002) reported that, in
addition to region II-plus, CSP has other regions involved in
the binding to liver cells, resulting in the partial binding
inhibition by region II-plus.
Oligomerization of PbCSP-gp64 fusion protein
It has been reported that the oligomerization of native
CSP on the surface of sporozoites may facilitate effective
binding to hepatocytes (Cerami et al., 1992, 1994; Sinnis et
al., 1994). To examine the degree of oligomerization of the
PbCSP-gp64 fusion protein, AcNPV-CSPsurf virions were
treated with different concentrations of 2-mercaptoethanol
(2-ME) and analyzed by SDS–PAGE. Fig. 4 shows that the
Fig. 3. Binding of AcNPV-CSPsurf virions to HepG2 cells and the effects
of region II-plus peptide, heparin, and heparinase I on binding. The fol-
lowing four assays were performed as described under Materials and
methods. (1) HepG2 cells were incubated with baculovirus virions (1 
109PFU) for 1 h followed by the addition of anti-gp64 MAb and alkaline
phosphatase-conjugated antimouse IgG. Bound enzyme was measured by
a fluorescent substrate. (2) Baculovirus virions (1  109PFU) were added
to HepG2 cells preincubated with 70 M region II-plus peptide. Binding
activity was measured as described. (3) Baculovirus virions (1  109PFU)
were incubated with heparin (10 IU/ml) before its addition to HepG2 cells.
Binding activity was measured as described. (4) HepG2 cells were prein-
cubated with heparinase I (5 U/ml) for 2 h followed by the addition of
baculovirus virions (1  109PFU). Binding activity was measured as
described. Data are presented as the mean  SEM of triplicate wells from
three independent experiments.
Fig. 2. Western blot analysis of recombinant baculoviruses is shown by (A)
immunoblotting of Sf9 cells infected with AcNPV-CSP (lanes 2, 6), Ac-
NPV-CSPsurf (lanes 3 and 7), or wild-type baculovirus (lanes 4 and 8)
performed using anti-PbCSP MAb (lanes 1–4) or anti-FLAG M2 MAb
(lanes 5–8). As a control, sporozoites isolated from the salivary gland of
the A. stephensi mosquito were immunoblotted (lanes 1 and 5). (B) Im-
munoblotting of purified AcNPV-CSP virions (lanes 1 and 3) or purified
AcNPV-CSPsurf virions (lanes 2 and 4) was performed using anti-PbCSP
MAb (lanes 1 and 2) or anti-gp64 MAb (lanes 3 and 4). Positions of
PbCSP-gp64 fusion protein and gp64 are indicated. Baculovirus virions
were purified as described under Materials and methods.
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PbCSP-gp64 fusion protein was detected in multiple forms
under nonreducing and partially reducing conditions con-
taining 103, 102, and 1% 2-ME. These results suggest
that most of the PbCSP-gp64 fusion protein on the virion
surface exists in an oligomeric form.
Protective efficacy of AcNPV-CSsurf against challenge
To study the protective efficacy of AcNPV-CSPsurf viri-
ons as a baculovirus-based vaccine in an experimental sys-
tem emulating the natural route of malarial infection,
BALB/c mice immunized intramuscularly (im) with two or
three doses of AcNPV-CSPsurf virions were challenged by
bites of P. berghei-infected mosquitoes. Protection was de-
fined either as the complete absence of blood-stage para-
sitemia from 3 to 21 days postchallenge (complete protec-
tion) or as the delayed onset of parasitemia compared to
naı¨ve control groups (partial protection). Although, in our
challenge method using mosquito bites, 100% of partially
protected mice with delayed onset of parasitemia resulted in
death, Sauzet et al. (2001) reported that 1-, 2-, or 3-day
delayed onset of parasitemia relative to naı¨ve control mice
would represent 80, 96, and 99.2% reductions in liver par-
asite burden, respectively, indicating that the delayed onset
of parasitemia could be utilized as an important parameter
of protection efficacy. Therefore, we estimated the protec-
tion efficacy by using both complete and partial protection.
Parasitemia of naı¨ve control mice occurred 5 days or less
after challenge in three experiments. In Experiment 1, 13 of
20 mice (63%) were completely protected. Of the 7 infected
mice, 5 achieved partial protection, with 3 mice being de-
layed by 1 day, 1 mouse being delayed by 2 days, and 1
mouse being delayed by 3 days. Overall, 18 (90%) of 20
mice immunized with AcNPV-CSPsurf virions were par-
tially or completely protected. It is also important to em-
phasize that inoculation with AcNPV-CSP had no effect on
the course of infection relative to naı¨ve controls (Table 1,
Experiment 1). Similarly, in Experiments 2 and 3, 90% of
mice immunized with AcNPV-CSPsurf virions were par-
tially or completely protected and 60% were completely
protected (Table 1, Experiments 2 and 3).
Evaluation of immune responses induced by immunization
To understand the potential relationship between hu-
moral responses and protection in mice immunized with
AcNPV-CSPsurf virions im, the prechallenge antibody re-
sponses to sporozoites were assessed by an indirect fluores-
cence antibody test (IFAT). High IFAT titers (mean titer,
1:28,700) were induced in mice immunized im twice or
three times with AcNPV-CSPsurf virions in the three ex-
periments (see Table 1). When mice immunized with Ac-
NPV-CSPsurf virions in Experiments 1 and 2 were re-
grouped into completely protected mice (n 19) or infected
mice (partially protected and nonprotected) (n  11), the
mean IFAT titer was slightly higher for the protected mice
(1:37,600) than for the infected mice (1:13,500) (Fig. 5A),
Fig. 4. Western blot analysis of AcNPV-CSPsurf virions under partially
reduced conditions is shown. AcNPV-CSPsurf virions were treated with
103, 102, or 1% 2-ME or without 2-ME before SDS–PAGE. Immuno-
blotting of these samples was performed using anti-PbCSP MAb, 3D11.
Table 1














Naive 1:50 5.0 (5) 0/10 (0) 0/10 (0)
recBAC-CSP im (3) 1:50 4.5 (4–5) 0/10 (0) 0/10 (0)
recBAC-CSProof im (3) 1:2,000–128,000 6.1 (5–8) 18/20 (90) 13/20 (63)
Experiment 2
Naive 1:50 4.2 (4–5) 1/10 (20) 1/10 (10)
recBAC-CSProof im (2) 1:2,000–128,000 6.3 (5–8) 9/10 (90) 6/10 (60)
Experiment 3
Naive 1:50 4.3 (4–5) 0/10 (0) 0/10 (0)
recBAC-CSProof im (3) 1:4,000–128,000 6.2 (5–8) 9/10 (90) 6/10 (60)
a The prepatent period in the interval between challenge and the detection of parasitemia
b Partial protection was defined as a delayed onset of parasitemia compared with naive control groups (6 or longer prepatent days).
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although this difference was not statistically significant.
Seven mice with IFAT titers  1:64,000 were all protected
against the first challenge. In contrast, 11 of 23 mice with
IFAT titers  1:32,000 in both groups were infected, al-
though 2 mice with the lowest IFAT titer (1:2,000) were
protected. No detectable CSP-specific antibody was induced
in groups of naı¨ve mice or mice immunized with AcNPV-
CSP virions, which all became infected. The levels of an-
tibodies of gp64 in groups receiving AcNPV-CSPsurf viri-
ons were comparable to those immunized with AcNPV-CSP
virions (data not shown). The finding that about half of the
mice (12 of 23) with IFAT titers  1:32,000 in both groups
were completely protected may explain variations in the
Th-1 and Th-2 ratio bias of the induced immune response.
To examine the type of immune response, the levels of IgG1
and IgG2a isotype antibodies specific for recombinant
PbCSP (rPbCSP) were measured by ELISA (Fig. 5B). All
three nonprotected mice had a low IgG1 antibody (0.2),
whereas 7 mice with a high IgG1 antibody (0.8), the same
mice with IFAT titers 1:64,000, were all completely pro-
tected. Although the mean ratio of IgG1/IgG2a was signif-
icantly higher in the completely protected mice (1.48 
0.32) than in the infected mice (0.7  0.13) (Mann–Whit-
ney U test: P 0.05), it is unlikely that complete protection
is simply due to Th-2 type response because about 40% of
the completely protected mice were plotted in low IgG1
(0.4) or low IgG1/IgG2a ratios (1.0) together with the
partially protected mice.
Since IFN- is a critical component of antimalaria liver-
stage protective response, we focused on evaluating the
levels of this cytokine secreted in splenocyte culture.
Splenocytes were obtained from naı¨ve control mice and
mice immunized with AcNPV-CSPsurf virions, and the
frequencies of splenocytes secreting IFN- in response to
PbCSP were measured by ELISPOT. Of four mice immu-
nized with AcNPV-CSPsurf virions, a low but significant
level of IFN- secretion (P  0.05) was detected in two
mice with high IgG1/IgG2a ratios (4.55 and 8.55), whereas
no significant IFN- secretion was detected in another two
mice with low IgG1/IgG2a ratios (0.22 and 0.44).
Protection against rechallenge
To examine the duration of complete protection in these
animals, 13 mice completely protected in Experiment 1 (see
Table 1) were rechallenged 60 days after the first parasite
challenge. All 5 mice (38%) with IgG1 predominant anti-
bodies at the first challenge were protected against rechal-
lenge (Table 2, mice 7–11), whereas another 8 mice with
IgG2a predominant antibodies at the first challenge became
infected (mice 12–19). The IgG1/IgG2a ratios between the
completely protected and the infected mice were signifi-
cantly different (P 0.01). Noticeably, the IFN- responses
from the splenocytes of mice protected against rechallenge
were dramatically elevated, indicating that priming of the
CSP-specific cell-mediated immune response by immuniza-
tion with AcNPV-CSsurf virions could be boosted by nat-
ural sporozoite challenge.
Discussion
In this study, we generated a recombinant baculovirus
displaying PbCSP on the virion surface. We chose the
baculovirus display system as a new malaria vaccine vehicle
because this system has the ability to display a foreign
protein in a native form due to the similarities in protein
Fig. 5. Humoral responses among protected and infected mice immunized with AcNPV-CSPsurf virions. Sera from immunized mice were collected by tail
cut bleeding 2 weeks after the final vaccination followed by challenge. Sera from groups of BALB/c mice immunized with AcNPV-CSPsurf virions in
Experiments 1 (n  20) and 2 (n  10) (see Table 1) were divided into two groups, protected n  19 (F) and infected (partial protection n  8 ( ) and
nonprotected n  3 (‚) mice. (A) End point IFAT titer to air-dried P. berghei sporozoites were plotted in the two groups. Bold bar indicates the IFAT titer
at 1:64,000. An IFAT titer at  1:64,000 led all mice to complete protection. (B) Sera from individual mice were diluted at 1:2000 and tested for IgG1 and
IgG2a subclasses by ELISA against rPbCSP. The absorbances of OD405 nm for anti-rPbCSP IgG1 and IgG2a were plotted in three groups: complete
protection (F), partial protection ( ), nonprotection (‚).
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processing and posttranslational modification between in-
sect and mammalian systems. Moreover, compared with
other viral-like particles, such as the hepatitis B core parti-
cle, baculovirus virions can incorporate not only antigen
epitopes but also full-length antigens. AcNPV-CSPsurf viri-
ons generated in this study have several notable character-
istics, including (1) PbCSP oligomerization on the virion
surface and (2) a high binding affinity for HepG2 cells
through HSPGs. These properties are in good agreement
with those of native CSP on the surface of sporozoites.
The main objective of this study was to test these “sporo-
zoite-like” CSP baculovirus virions for their ability to pro-
tect animals against malaria sporozoite challenge. In three
independent experiments, 60% of BALB/c mice immunized
with AcNPV-CSPsurf virions were completely protected
against challenge by mosquito bites. We and other groups
have chosen the bites of sporozoite-infected mosquitoes as
the route of sporozoite challenge because mosquito-injected
sporozoites are more natural and infectious than iv inocu-
lated sporozoites (Leitner et al., 1997; Vaughan et al., 1999;
Yoshida et al., 2000). More importantly, it should be noted
that sporozoite vaccine trials with humans invariably utilize
the bites of sporozoite-infected mosquitoes as their chal-
lenge model system (Church et al., 1997; Ockenhouse et al.,
1998; Stoute et al., 1997) In this study, the 70–90% of
partial and complete protective efficacies against challenge
by mosquito bites should be sufficient to pursue the bacu-
lovirus display system as a new malaria vaccine.
A limited number of studies have been published ad-
dressing the issue of protection against multiple sporozoite
challenge infections. In a human trial of the RTS,S malaria
vaccine, 88% (7 of 8) of volunteers receiving “RTS,S vac-
cine 3” were protected against the first challenge by mos-
quito bites, while 20% (1 of 5) of the protected volunteers
were protected against rechallenge (Stoute et al., 1997). In
this study, 38% (5 of 13) of mice completely protected
against the first challenge, which had PbCSP-specific IgG1
predominant antibodies, were completely protected against
rechallenge. Generally speaking, an increased IgG1:IgG2a
ratio suggests a bias toward the activation of a Th-2 type
cytokine response. In this study, low levels of IFN-, a Th-1
type cytokine, were secreted by splenocytes from mice with
IgG1 predominant antibody responses following AcNPV-
CSPsurf virion immunization. Moreover, sporozoite chal-
lenge by bites with infected mosquitoes appeared to boost
the IFN- response in the protected mice having an IgG1-
predominant antibody response. The observation that mice
protected against rechallenge were characterized by IgG1-
dominant antibodies as well as high levels of IFN- is
inconsistent with a simple Th-1:Th-2 dichotomous mecha-
nism for immunity to sporozoite infection. Thus, the results
of the assays used do not always correlate with the fates of
all individual mice after challenge, indicating that AcNPV-
CSPsurf virion vaccination could induce a complex inter-
action between Th-1 and Th-2 responses. This hypothesis
requires further investigation in studies measuring the levels
of both Th-1 and Th-2 cytokine-producing cells in mice
immunized with AcNPV-CSPsurf virions.
Baculovirus AcNPV has been used as a vector for the
delivery of genes to mammalian cells in vitro. Based on the
finding that AcNPV-CSPsurf has a 12-fold higher binding
activity to HepG2 cells than wild-type AcNPV, baculovirus
virions displaying PbCSP may be an effective liver-targeted
gene delivery vehicle. Baculovirus itself is capable of ad-
herence to mammalian cells using gp64 as a receptor for
phospholipids on the host cell surface and viral entry into
the cells is mediated by endocytosis following membrane
fusion (Tani et al., 2001). In the case of baculovirus virions
displaying CSP, hepatocyte-binding activity may be en-
Table 2
IgGl/IgG2a ratio and the frequencies of IFN--producing cells in
AcNPV-CSP surf virions-immunized mice




Mouse 1 1:50 NTd 2.0  0.86
Mouse 2 1:50 NT 1.0  0.45
Mice immunized im with
AcNPV-CSPsurf
virionsa
Mouse 3 1:2,000 4.55 38.0 5.01*
Mouse 4 1:2,000 0.44 4.67 0.80
Mouse 5 1:16,000 8.55 12.8 2.55*
Mouse 6 1:16,000 0.22 4.67 1.56
Mice protected against
rechallengeb
Mouse 7 1:2,000 2.00 437 10.17*
Mouse 8 1:16,000 1.25 135 5.98*
Mouse 9 1:32,000 3.57 256 4.68*
Mouse 10 1:64,000 3.70 387 7.82*
Mouse 11 1:64,000 5.55 NT
Mice infected against
rechallenge
Mouse 12 1:2,000 0.37 NT
Mouse 13 1:4,000 0.97 NT
Mouse 14 1:8,000 0.49 NT
Mouse 15 1:16,000 0.55 NT
Mouse 16 1:32,000 0.56 NT
Mouse 17 1:64,000 0.33 NT
Mouse 18 1:64,000 0.71 NT
Mouse 19 1:128,000 0.82 NT
a Mice were immunized im three times with AcNPV-CSPsurf virions.
Three weeks after the final immunization, sera and splenocytes were taken
from each mouse.
b In experiment 1, 13 mice immunized im three times with AcNPV-
CSPsurf virions were protected against challenge. Of these mice, 5 mice
were protected against rechallenge. Splenocytes were taken from 4 of 5
mice individually 60 days after rechallenge. Sera taken prior to first
challenge were used for IFAT and IgGl/IgG2a assays.
c Frequencies of splenocytes secreting IFN- is response to rPbCSP
were measured by ELISPOT. Data represent the mean number  SEM of
SPCs from triplicate cultures of individual mice.
d Not tested.
* Statistical significances between naive and immunized mice were
determined by Student’s r test (P  0.05).
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hanced as a result of the interaction of the virion with both
gp64 and CSP receptors on the hepatocyte surface. The
baculovirus gene transfer system offers considerable poten-
tial for development as a gene delivery vehicle due to its
lack of pathogenicity in mammalian cells, its long history of
safe usage in research laboratories, its large capacity to
harbor foreign DNA, and the production of high virus titers
in tissue culture. However, the in vivo applicability of
baculovirus-mediated gene transfer may be hampered by its
susceptibility to the complement system. Recently, a bacu-
lovirus displaying a decay-accelerating factor (DAF) on the
virion surface has been shown to exhibit strong complement
resistance in in vitro assays (Huser et al., 2001). The use of
a baculovirus displaying both DAF and CSP would be
expected to improve its effectiveness for liver-directed gene
transfer in vivo.
Another particularly important consideration for vaccine
use in developing countries is its cost effectiveness and the
reuse of multiple foreign antigens over time. Baculovirus
displaying an epitope tag linked to target antigens, such as
the FLAG epitope used in this study, could easily be puri-
fied from a serum-free insect culture supernatant using a
one-step affinity column. The simplicity of production and
purification should translate to the economical large-scale
manufacturing of this vaccine. Antivector immunity may
seriously reduce the reuse potential of live viral or bacterial
vectors by the inhibition of vector proliferation. A passively
derived maternal antibody may also be a potential hurdle for
vaccination in children less than 1 year of age. Unlike such
live vectors, baculovirus virions displaying foreign antigens
are subunit vaccines and could induce immunity against
foreign antigens in the presence of antibaculovirus immu-
nity. In addition, baculovirus virions incapable of replicat-
ing DNA in mammalian hosts may provide the greatest
level of safety.
In summary, we report for the first time that a baculovi-
rus display system may be effectively used as a vaccine
vehicle in the absence of extraneous immunological adju-
vants to provide protective immunity against infection. The
exceptional immunogenicity of this vaccine vehicle may be
due to the optimal display of native epitopes in oligomeric
arrays as well as the potential carrier and adjuvant effects of
viral structural proteins. The ultimate goal of any vaccina-
tion strategy is to induce a specific, long-lasting immune
response that protects the individual from infection with a
given pathogen.
Future studies will attempt to improve the efficacy of this
baculovirus display vaccine system using prime-boost im-
munization strategies or the addition of a blood-stage anti-
gen, such as the merozoite surface protein 1, to the display
system. The value of this system for in vivo liver-directed
gene transfer and the extension of these studies to evaluate
the expression of transferred genes within hepatocytes also
merit further investigation.
Materials and methods
Mice, parasites, and mosquitoes
Female BALB/c mice were obtained from SEASCO
(Saitama, Japan) and used at 7 to 8 weeks of age in all
experiments. The P. berghei ANKA strain was maintained
by cyclical passage through BALB/c mice and Anopheles
stephensi (SDA 500 strain). P. berghei-infected mosquitoes
taken 14 days after an infectious blood meal were used to
challenge immunized and naı¨ve control mice.
Plasmid construction
A baculovirus transfer vector, pBACsurf-CSP, was con-
structed by excision of the gene fragment encoding for
amino acids 21–306 of PbCSP from pcDNA-CS87 (Yoshi-
da et al., 2000) by digestion with PstI and SmaI. The excised
fragment was cloned into the PstI/SmaI sites of pBACsurf
(Novagen, Madison, WI). A baculovirus transfer vector,
pBACgus-CSP, was constructed by excision of the gene
fragment encoding amino acids 21–306 of PbCSP from
pcDNA-CS87 by digestion with BamHI and NotI and liga-
tion into the BamHI/NotI sites of pBACgus-1 (Novagen).
Recombinant baculoviruses and cells
The recombinant baculoviruses AcNPV-CSPsurf and
AcNPV-CSP were generated in Spodoptera frugiperda
(Sf9) cells by cotransfection of the recombinant transfer
plasmids pBAC-CSPsurf and pBAC-CSP, respectively,
with BacVector-3000 DNA (Novagen) according to the
manufacturer’s protocol. Baculoviruses were grown and
assayed in Sf9 cells using SF900-II medium (Life Technol-
ogies, Inc., Rockville, MD) supplemented with 1% penicil-
lin and 100 U/ml of streptomycin at 27°C. For purification
of the recombinant baculoviruses, culture supernatants were
harvested 4 days after infection, and budded virions were
purified on 10–60% (w/v) sucrose gradients as described
previously (Sandig et al., 1996). The virions were resus-
pended in phosphate-buffered saline (PBS) and infectious
titers were determined by plaque assay. For protein produc-
tion, High Five cells derived from a Trichoplusia ni egg
(Invitrogen, San Diego, CA) were maintained in Ex-Cell
405 medium (JRH Bioscience, Lenexa, KS) as described
previously (Yoshida et al., 1999). Hepatoma cell line
HepG2 cells (American Type Cell Culture, Rockville, MD)
were maintained at 37°C in RPMI 1640 supplemented with
10% fetal calf serum (FCS), 1% penicillin, and 100 U/ml of
streptomycin.
Expression and purification of recombinant PbCSP
High Five cells (1.5  106 cells/ml) were infected with
AcNPV-CSP at a m.o.i of 3 and incubated at 27°C for 3
days. Recombinant PbCSP (rPbCSP) was purified from
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culture supernatants by affinity chromatography on a Ni-
NTA Superflow column (Qiagen GmbH, Hiden, Germany)
following chromatography on a Q-Sepharose anion ex-
change column (HiPrep 16/10 QXL, Pharmacia Biotech,
Uppsala, Sweden). The purity of the protein was checked by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS–PAGE), and the protein yield was estimated by com-
parison with BSA standards. The highly purified rPbCSP
was used as an enzyme-linked immunosorbent assay
(ELISA) antigen.
Immunoblotting
Protein extracts from baculovirus-infected insect cells
and baculovirus virions were prepared as described previ-
ously (Mottershead et al., 2000). The protein samples were
separated on a 6 or 8% SDS–PAGE gel, transferred to an
Immobilon Transfer Membrane (Millipore, Bedford, MA),
and probed with either the anti-PbCSP monoclonal antibody
(MAb) 3D11 (kindly provided by Dr. Ruth Nussenzweig),
anti-FLAG M2 MAb (Eastman Kodak Co., Rochester, NY),
or anti-AcNPV gp64 MAb (BD Biosciences Clonetech,
Palo Alto, CA) as indicated. Bound antibodies were subse-
quently detected as described previously (Yoshida et al.,
1999).
Cell-binding assay
Assays were performed according to the methods de-
scribed by Rathore and McCutchan (2000). In brief, HepG2
cells at a density of 1  105 cells per well were fixed with
4% paraformaldehyde followed by blocking with TBS (20
mM Tris–HCl, pH 7.5, 150 mM NaCl) containing 1%
bovine serum albumin (BSA) in a 96-well black plate
(Corning Costar, Tokyo, Japan). Baculovirus virions (1 
109 PFU) were incubated with cells for 1 h, and cells were
washed to remove unbound virions and incubated with
anti-gp64 MAb for 1 h followed by alkaline phosphatase-
coupled antimouse IgG for 30 min. The 4-methylumbel-
liferyl phosphate (4-MUP) liquid substrate system (Sigma-
Aldrich, Tokyo, Japan) was used as substrate, and
fluorescence was measured using Fluoroskan Ascent
(Thermo Labsystems, Vantaa, Finland) with excitation at
350 nm and emission at 460 nm according to the manufac-
turer’s instructions. All of the experiments were repeated
three times.
Binding inhibition by synthetic peptide, heparin, and
heparinase 1
Region II-plus synthetic peptide EWSQCNVTCGS-
GIRVRKRKGSN (Eichinger et al., 1986) was purchased
from Hokkaido System Science (Sapporo, Japan). For com-
petition assays using the region II-plus synthetic peptide,
HepG2 cells were incubated with 70 M region II-plus
synthetic peptide for 2 h before the addition of baculovirus
virions (1  109 PFU). The cell-binding assay was per-
formed by incubation with anti-gp64 MAb as described
above using the 4-MUP detection system.
To evaluate the effect of heparin on the binding activity
of baculovirus virions, baculovirus virions (1  109 PFU)
were preincubated with 10 IU/ml of heparin (Sigma-Al-
drich) for 15 min at 37°C before addition to the HepG2
cells. The cell-binding assay was performed using the
4-MUP system followed by incubation with anti-gp64 MAb
as described above.
To determine the effect of HSPGs on the binding activity
of baculovirus virions, HepG2 cells were treated with 5
U/ml of heparinase I (Sigma-Aldrich) in 10 mM phosphate
buffer (pH 6.0) containing 150 mM NaCl, 3 mM KCl, 0.5
mM MgCl2, 1 mM CaCl2, 0.1% glucose, and 0.5% BSA.
Cells were washed once in PBS and then incubated with
baculovirus virions (1  109 PFU). The cell-binding assay
was performed by incubation with anti-gp64 MAb as de-
scribed above. All experiments were repeated three times.
Immunization and challenge infections
Experiment 1
Mice were immunized im three times at 4-week intervals
with 1  108 PFU of baculovirus virions. Two weeks after
the third immunization, all groups of mice were anesthe-
tized and individually exposed to the bites of at least five
sporozoite-infected A. stephensi mosquitoes over 5 min.
After feeding, the mosquitos’ salivary glands were dissected
and it was microscopically confirmed that 100% of the
mosquitoes used for blood feeding were sporozoite-in-
fected, as described previously (Leitner et al., 1997; Yo-
shida et al., 2000). Beginning 3 days after challenge, mice
were checked daily for P. berghei infection by the micro-
scopic examination of Giemsa-stained thin smears of tail
blood. A minimum of 25 fields ( 400) was read before a
mouse was determined to be negative for infection. Mice
with negative blood smears were monitored for blood par-
asites for up to 21 days after challenge. Sixty days after
challenge, protected mice were rechallenged by the bites of
P. berghei-infected A. stephensi as described above.
Experiment 2
Mice were immunized twice at 3-week intervals via the
im route with 1  108 PFU of baculovirus virions. Two
weeks after the second immunization, all groups of mice
were challenged by bites of P. berghei-infected A. stephensi
as described above.
Experiment 3
Mice were immunized three times at 3-week intervals via
the im route with 1  108 PFU of baculovirus virions. Two
weeks after the third immunization, all groups of mice were
challenged by bites of P. berghei-infected A. stephensi as
described above.
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Antibody assays
Sera from immunized mice were collected by tail bleeds
2 weeks after the final vaccination, prior to sporozoite chal-
lenge. P. berghei sporozoite-specific IFAT titers were de-
termined using salivary gland sporozoites produced from P.
berghei-infected A. stephensi mosquitoes as described pre-
viously (Charoenvit et al., 1987). In brief, twofold serial
dilutions of sera from individual mice were reacted on
multispot antigen slides containing 1000 air-dried sporozo-
ites, and antibodies were detected using fluorescein isothio-
cyanate-conjugated rabbit antimouse IgG.
For analysis of IgG subclass antibodies against PbCSP, a
96-well assay plate (Corning Costar) was coated with rP-
bCSP at 1 mg/ml in carbonate buffer (pH 9.6) and then
blocked with 1% BSA (Sigma-Aldrich) in TBS buffer. Sera
from individual mice were diluted 1:2000 in TBS and added
to the appropriate wells in triplicate, followed by peroxi-
dase-conjugated rat antimouse IgG1 or IgG2a antibodies
(Zymed, San Francisco, CA). Peroxidase substrate solution
[H2O2 and 2,2-azino-bis(3-ethylbenzothiazoline-6-sulfo-
nate)] was added to each well and the absorbance value at
405 nm was measured using a Multiskan BICHROMATIC
microplate reader (Thermo Labsystems, Vantaa, Finland).
Data were analyzed and compared by the Mann–Whitney U
test.
ELISPOT assays
PbCSP-specific IFN--producing cells were determined
by enzyme-linked immunospot (ELISPOT) as described
previously (Currier et al., 2002). In brief, 96-well plates
(MultiScreen IP Filtration plate MAIPS45 10, Millipore)
were coated with 15 g/ml of the antimouse IFN- MAb
R4-6A2 (PharMingen, San Diego, CA) in 50 l of 0.1 M
NaHCO3. After overnight incubation at 4°C, the wells were
washed with PBS and blocked for 2 h at 37°C with 200 l
of RPMI 1640 containing 10% FCS. Splenocytes from
immunized mice were resuspended to 1 107 cells/ml (1
106 cells/well) and placed in triplicate into antibody-coated
wells, and rPbCSP (10 g/ml) was added to each test well.
After 20 h of incubation at 37°C, the plates were washed six
times with PBS containing 0.05% Tween 20 (PBST) and
once with water, incubated for 2 h at room temperature with
a solution of 1 mg/ml of biotinylated antimouse IFN-MAb
XMG1.2 (PharMingen, San Diego, CA), washed six times
with PBST, and incubated for 2 h with 50 l of a 1 g/ml
solution of streptavidin–alkaline phosphatase conjugate
(PharMingen), both at room temperature. Spots were devel-
oped by adding 100 l of 5-bromo-4-chloro-3-indolylphos-
phate p-toludin salt/nitroblue tetrazolium chloride (BCIP/
NBT Alkaline Phosphatase Substrate kit IV; Vector
Laboratories, Inc., Burlingame, CA), and reactions were
stopped by a water wash. Spot-forming cells (SFCs) were
enumerated using the KS ELISPOT system (Carl Zeiss,
Hallbergmoos, Germany). Data represent the means SEM
of SFCs from triplicate cultures of individual mice. Data
were analyzed and compared by Student’s t test.
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